Vaccinia virus recombinant DAL protein and orthopoxvirus vaccine composition comprising the same
A gene construct encoding a recombinant DAL protein, incorporating specific peptides, enables high immunogenicity and easy purification of vaccinia virus antigen proteins in a plant system, addressing the limitations of existing vaccines and enhancing orthopoxvirus protection.
Patent Information
- Application Number
- KR1020240150087
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-10-29
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-10-29
AI Technical Summary
Existing vaccines do not effectively express vaccinia virus antigen proteins in a water-soluble form with high immunogenicity, limiting their efficacy as orthopoxvirus vaccines.
A gene construct encoding a recombinant DAL protein, comprising specific amino acid sequences from vaccinia virus antigens, is used to produce a vaccinia virus recombinant antigen protein in a plant expression system, incorporating endoplasmic reticulum signal and retention peptides, and a His-tag for easy isolation and purification.
The recombinant DAL protein is expressed in a water-soluble form with high immunogenicity, facilitating easy isolation and purification, and generates neutralizing antibodies to prevent orthopoxvirus infections.
Smart Images

Figure 112024118409878-PAT00003_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a vaccinia virus recombinant protein and an orthofox virus vaccine composition containing the same. Background Technology
[0003] Smallpox is an acute disease characterized by fever, blisters, and pustular pathological skin changes, caused by the smallpox virus. It has a very high mortality rate and once accounted for 10% of all causes of death worldwide, including in Korea; however, in 1979, smallpox was declared eradicated globally. Nevertheless, following the report of a single case of monkeypox in the UK on May 7, 2022, cases of infection have been reported in numerous countries including the United States, Brazil, Spain, France, and Colombia, and interest has recently been growing again as the possibility of the smallpox virus being used as a biological terror weapon has become known.
[0004] In Korea, monkeypox was designated as a Class 2 infectious disease on June 8, 2022, and the crisis level was raised from 'concern' to 'caution' after a Korean national who had visited Germany was confirmed to have monkeypox in June of the same year. Consequently, the need for the development of vaccines to prevent orthofoxviruses, including monkeypox, is emerging.
[0005] Meanwhile, A17L, A27L, A28L, A33R, B5R, D8L, L1R, and H3 have been reported as vaccinia virus proteins identified as targets of neutralizing antibodies in humans (Non-patent Literature 1).
[0006] Against this background, the inventors developed a gene construct derived from major antigens of vaccinia virus and a recombinant vector containing the same for high-efficiency production in plants, and completed the present invention by demonstrating the efficacy of a recombinant protein produced using the said recombinant vector as a vaccine. Prior art literature
[0008] Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. Viruses. 2022 Sep 3;14(9):1960. The problem to be solved
[0009] The present invention was devised to solve the aforementioned problem and aims to provide a gene construct designed so that a derived vaccinia virus antigen protein can be expressed in a water-soluble form while having high immunogenicity.
[0010] The present invention also aims to provide a vaccinia virus DAL antigen protein prepared using a recombinant vector and / or transformant comprising the aforementioned gene construct, and an orthophoxvirus vaccine composition comprising the same.
[0011] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below. means of solving the problem
[0013] To solve the above problem, the present invention provides a gene construct comprising a polynucleotide encoding a vaccinia virus recombinant DAL protein, comprising an amino acid sequence from position 90 to 181 in the amino acid sequence of SEQ ID NO. 1, an amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO. 2, an amino acid sequence from position 64 to 181 in the amino acid sequence of SEQ ID NO. 1, and an amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO. 2.
[0014] In the present invention, the recombinant DAL protein may include the amino acid sequence of SEQ ID NO. 3.
[0015] In the present invention, the gene construct may further comprise a polynucleotide encoding an endoplasmic reticulum signal peptide and / or a polynucleotide encoding an endoplasmic reticulum retention signal peptide.
[0016] In the present invention, the gene construct may further comprise a polynucleotide encoding a His-tag.
[0017] In the present invention, the polynucleotide encoding the endoplasmic reticulum signal peptide (ER signal peptide) may include the nucleotide sequence of SEQ ID NO. 5 encoding a new chaperone binding protein (NB).
[0018] In the present invention, the endoplasmic reticulum residual signal peptide may comprise the amino acid sequence of HDEL (His-Asp-Glu-Leu), HEEL (His-Glu-Glu-Leu), KDEL (Lys-Asp-Glu-Leu), KEEL (Lys-Glu-Glu-Leu), RDEL (Arg-Asp-Glu-Leu) or REEL (Arg-Glu-Glu-Leu).
[0019] In the present invention, the gene construct may be formed by sequentially connecting the following (i) to (v):
[0020] (i) Polynucleotide encoding an endoplasmic reticulum signal peptide,
[0021] (ii) a polynucleotide encoding the recombinant DAL protein,
[0022] (iii) Polynucleotide encoding the His-tag and
[0023] (iv) Polynucleotide encoding an ER retention signal peptide.
[0024] In the present invention, the gene construct may include the nucleotide sequence of SEQ ID NO. 13.
[0025] In addition, the present invention provides a recombinant vector comprising the aforementioned gene construct and a transformant transformed by said recombinant vector.
[0026] In the present invention, the transformant may be a plant body.
[0027] In addition, the present invention provides a method for producing a vaccinia virus recombinant antigen protein comprising the following (a) and (b):
[0028] (a) a step of transforming the aforementioned recombinant vector into a plant; and
[0029] (b) A step of isolating and purifying vaccinia virus recombinant DAL protein from the above plant.
[0030] In the present invention, the vaccinia virus recombinant DAL protein may be expressed in a water-soluble form in the plant body.
[0031] In addition, the present invention provides a vaccinia virus recombinant antigen protein comprising the amino acid sequence of SEQ ID NO. 3.
[0032] In the present invention, the vaccinia virus recombinant antigen protein may be prepared using the aforementioned recombinant vector.
[0033] In addition, the present invention provides an orthophoxvirus vaccine composition comprising the vaccinia virus recombinant antigen protein described above.
[0034] In the present invention, the orthopoxvirus may be a smallpox virus, a vaccinia virus, or a monkeypox virus. Effects of the invention
[0036] The vaccinia virus recombinant DAL protein prepared using a recombinant vector containing a gene construct according to the present invention has high immunogenicity as an antigen and is expressed in a water-soluble form in a plant expression system, making isolation and purification easy.
[0037] In addition, the vaccine composition containing the vaccinia virus recombinant DAL protein according to the present invention has the effect of preventing infection with Orthofoxviruses by generating neutralizing antibodies against Orthofoxviruses.
[0038] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description of the invention or the claims. Brief explanation of the drawing
[0040] FIG. 1 shows a gene construct [DAL:6H] encoding a vaccinia virus recombinant DAL protein according to one embodiment of the present invention, the base sequence thereof, and the amino acid sequence of the expressed recombinant DAL protein. FIG. 2 is a band image obtained by performing a Western blot to confirm the expression of vaccinia virus recombinant DAL protein according to one embodiment of the present invention (T, Total extract; S, Soluble; P, Pellet). Figure 3 shows the results of confirming a protein sample obtained during the process of isolating and purifying vaccinia virus recombinant DAL protein according to one embodiment of the present invention by electrophoresis followed by Western blot (A) and Coomassie blue staining (B). Figure 4 is a graph showing the change in body weight (A) and survival rate (B) of mice following vaccinia virus challenge inoculation after administration of vaccinia virus recombinant DAL protein vaccine according to one embodiment of the present invention. Figure 5 is a PRNT result (A) and a graph (B) showing the reduction rate of vaccinia virus plaques compared to a control group (cultured only vaccinia virus) according to the dilution ratio of mouse serum after vaccination with vaccinia virus recombinant DAL protein vaccine according to one embodiment of the present invention. Specific details for implementing the invention
[0041] It should be noted that in the following description, only the parts necessary for understanding the embodiments of the present invention are described, and the description of other parts will be omitted to the extent that it does not detract from the gist of the present invention.
[0042] The terms and words used in this specification and claims described below shall not be interpreted as being limited to their ordinary or dictionary meanings, but shall be interpreted in a meaning and concept consistent with the technical spirit of the invention, based on the principle that the inventor may appropriately define the concept of the terms to best describe his invention.
[0043] Therefore, the embodiments described in this specification and the configurations illustrated in the drawings are merely preferred embodiments of the present invention and do not represent all technical concepts of the present invention; thus, it should be understood that various equivalents and modifications that can replace them may exist at the time of filing this application.
[0044] The present invention will be described in detail below.
[0045] As mentioned above, with monkeypox infection cases occurring simultaneously worldwide since 2022, the possibility of the smallpox virus being used as a biological weapon is emerging, and thus, in preparation for this, there is a need to develop a vaccine to prevent orthofoxviruses, including monkeypox.
[0046] Accordingly, in the present invention, a gene construct encoding a recombinant DAL protein was constructed by fusing A33_1 and A33_2, which are parts of A33, one of the major antigens of vaccinia virus, with L1_1, which is a part of the L1 protein. By confirming the protective efficacy against orthofoxovirus and the ability to generate neutralizing antibodies against it of the recombinant DAL protein produced therefrom, the efficacy of the said recombinant DAL protein as a vaccine was proven.
[0047] Accordingly, the first aspect of the present invention relates to a gene construct comprising a polynucleotide encoding a vaccinia virus recombinant DAL protein, comprising an amino acid sequence from position 90 to 181 in the amino acid sequence of SEQ ID NO. 1 (A33_1), an amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO. 2 (L1_1), an amino acid sequence from position 64 to 181 in the amino acid sequence of SEQ ID NO. 1 (A33_2), and an amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO. 2 (L1_1).
[0048] In the present invention, the amino acid sequence of SEQ ID NO. 1 is an amino acid sequence constituting the vaccinia virus A33 protein, and the amino acid sequence of SEQ ID NO. 2 is an amino acid sequence constituting the vaccinia virus L1 protein, which may be known in an open database such as NCBI, for example.
[0049] In the present invention, constructing the structure in the form of A33_1 - L1_1 - A33_2 - L1_1 may be intended to express the DAL protein in a water-soluble form while having high immunogenicity as an antigen.
[0050] In the present invention, the polynucleotide encoding the recombinant DAL protein may include or be composed of the nucleotide sequence of SEQ ID NO. 3, but may include without limitation any nucleotide sequence that exhibits substantially the same or corresponding efficacy as said nucleotide sequence, or is composed thereof. Specifically, it may include a nucleotide sequence having sequence homology of 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more with the nucleotide sequence of SEQ ID NO. 3. For example, it includes nucleotide sequences having sequence homology of 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and 100%. The “% of sequence homology” for a nucleotide sequence is determined by comparing two optimally arranged sequences with a comparison region, and a portion of the nucleotide sequence in the comparison region may include additions or deletions (i.e., gaps) compared to the reference sequence (which does not include additions or deletions) for the optimal arrangement of the two sequences.
[0051] As used herein, the term “polynucleotide” refers to an oligomer or polymer comprising two or more linked nucleotides or nucleotide derivatives, generally linked together by phosphodiester bonds, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Polynucleotides also include, for example, nucleotide analogs, or DNA and RNA derivatives comprising “backbone” bonds other than phosphodiester bonds, for example, phosphodiester bonds, phosphoramidate bonds, phosphorothioate bonds, thioester bonds, or peptide bonds (peptide nucleic acids). Polynucleotides include single-stranded and / or double-stranded polynucleotides, for example, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as analogs of either RNA or DNA.
[0052] The present invention also includes a polynucleotide having a base sequence substantially identical to the base sequence described above, and a fragment thereof. A polynucleotide having a substantially identical base sequence refers to a gene encoding a recombinant protein having the same function as that used in the present invention, regardless of sequence homology. A fragment of the polynucleotide also refers to a polynucleotide encoding a recombinant protein having the same function as that used in the present invention, regardless of the length of the fragment.
[0053] Furthermore, the amino acid sequence of the recombinant protein of the present invention may be obtained from various biological resources, such as microorganisms, within a range that does not affect the immunogenicity (antigenicity) of the protein, and proteins obtained from such other biological resources are also included within the scope of the present invention.
[0054] Accordingly, the present invention also comprises a polypeptide having a substantially identical amino acid sequence to the recombinant DAL protein and a fragment of said polypeptide. A polypeptide having a substantially identical amino acid sequence means a protein having the same function as used in the present invention, regardless of homology of the amino acid sequence. A fragment of said polypeptide also means a protein having the same function as used in the present invention, regardless of the length of the fragment.
[0055] The protein used in the present invention may have some of its amino acids substituted, and the amino acid substitutions of the present application may be non-conserved substitutions. Such non-conserved substitutions may include modifying amino acid residues of a target protein or polypeptide in a non-conserved manner, such as, for example, replacing an amino acid residue having a specific side chain size or specific characteristic (e.g., hydrophilicity) with an amino acid residue having a different side chain size or different characteristic (e.g., hydrophobicity).
[0056] The above amino acid substitutions may also be conserved substitutions. Such conserved substitutions may involve altering amino acid residues of a target protein or polypeptide in a conserved manner, for example, by replacing an amino acid residue having a specific side chain size or specific characteristics (e.g., hydrophilicity) with an amino acid residue having the same or similar side chain size or the same or similar characteristics (e.g., still hydrophilicity). Such conserved substitutions generally do not significantly affect the structure or function of the produced protein. In this application, amino acid sequence variants, fragments thereof, or variants thereof with one or more substituted amino acids that are mutants of a recombinant protein may include conserved amino acid substitutions that do not significantly alter the structure or function of the protein.
[0057] For example, mutual substitutions between amino acids in each of the following groups may be considered as conservative substitutions in this application:
[0058] Group of amino acids with nonpolar side chains: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.
[0059] Group of uncharged amino acids with polar side chains: glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
[0060] Negatively charged amino acid group with polar side chains: aspartic acid and glutamic acid.
[0061] Positively charged basic amino acid group: lysine, arginine, and histidine.
[0062] Amino acid groups containing phenyl: phenylalanine, tryptophan, and tyrosine.
[0063] The recombinant protein, polypeptide, and / or amino acid sequence included in the present invention may also be understood to include at least the following range: variants or homologues having the same or similar function as said recombinant protein or polypeptide.
[0064] In the present invention, the variant may be a protein or polypeptide produced by substitution, deletion, or addition of one or more amino acids compared to the amino acid sequence of the recombinant protein and / or polypeptide. For example, the functional variant may comprise a protein or polypeptide having an amino acid change by substitution, deletion, and / or insertion of at least one amino acid, e.g., 1-30, 1-20, or 1-10, or alternatively, substitution, deletion, and / or insertion of 1, 2, 3, 4, or 5 amino acids. The functional variant may substantially retain the biological properties of the protein or polypeptide prior to the change (e.g., substitution, deletion, or addition). For example, the functional variant may retain 60%, 70%, 80%, 90%, or 100% or more of the biological activity of the protein or polypeptide prior to the change.
[0065] In the present invention, the homologue may be a protein or polypeptide having at least about 80% sequence homology (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) with respect to the amino acid sequence of the protein and / or polypeptide.
[0066] In the present invention, the homology generally refers to similarity, analogousness, or association between two or more sequences. The “percent of sequence homology” can be calculated by comparing two aligned sequences in a comparison window that determines the number of positions where the same nucleic acid base (e.g., A, T, C, G, I) or the same amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) exists, and the number of matching positions in the comparison window (i.e., window size) is divided by the total number of positions to provide the percentage of sequence homology, and the result is multiplied by 100. Alignment for determining the percentage of sequence homology may be performed in various ways known in the art using publicly available computer software, such as, for example, BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art may determine appropriate parameters for sequence alignment, including any algorithms necessary to achieve maximum alignment within the full-length sequences being compared or within a target sequence region. Such homology may also be determined by the following methods: FASTA and BLAST. FASTA algorithms are described, for example, in WR Pearson and DJ Lipman's "Improved Tool for Biological Sequence Comparison", Proc. Natl. Acad. Sci., 85: 2444-2448, 1988; and D, J. Lipman and WRPearson's "Fast and Sensitive Protein Similarity Search", Science, 227:1435-1441, 1989 is disclosed, and a description of the BLAST algorithm is disclosed in S. Altschul, W. Gish, W. Miller, EW Myers and D. Lipman, "A Basic Local Alignment Search Tool", Journal of Molecular Biology, 215: 403-410, 1990.
[0067] The gene construct according to the present invention may further include a polynucleotide encoding an endoplasmic reticulum signal peptide and / or a polynucleotide encoding an endoplasmic reticulum retention signal peptide for the purpose of accumulating recombinant DAL protein at a high concentration in the endoplasmic reticulum.
[0068] In the present invention, the polynucleotide encoding the endoplasmic reticulum signal peptide and the polynucleotide encoding the endoplasmic reticulum residual signal peptide may each be located at the 5' end direction and the 3' end direction of the polynucleotide encoding the recombinant DAL protein.
[0069] That is, the endoplasmic reticulum signal peptide and the endoplasmic reticulum residual signal peptide can each be connected to the N-terminus and C-terminus of the recombinant DAL protein, respectively.
[0070] In the present invention, the endoplasmic reticulum signal peptide is located at the N-terminus of the recombinant DAL protein and serves to induce the newly synthesized protein to enter the endoplasmic reticulum (ER). The endoplasmic reticulum signal peptide according to the present invention is not limited in type or amino acid sequence as long as it is a plant endoplasmic reticulum signal peptide known to those skilled in the art, but preferably it may be a new chaperone binding protein (NB).
[0071] In the present invention, the polynucleotide encoding the NB may include or be composed of the nucleotide sequence of SEQ ID NO. 5, but may include without limitation any nucleotide sequence that exhibits substantially the same or corresponding efficacy as said nucleotide sequence, or be composed thereof. Specifically, it may include a nucleotide sequence having sequence homology of 80% or more, preferably 90% or more, and more preferably 95% or more with the nucleotide sequence of SEQ ID NO. 5.
[0072] As described above, the above NB is used to transfer the expressed recombinant protein to the endoplasmic reticulum, and when the recombinant DAL protein is expressed, a part of the sequence may be cut off so that only some amino acids remain, or the entire sequence may be cut off so that the signal peptide sequence region does not exist.
[0073] In the present invention, the endoplasmic reticulum residual signal peptide is located at the C-terminus of the recombinant DAL protein and serves to retain the protein when the protein present inside the endoplasmic reticulum exits to the Golgi apparatus through a secretion pathway. The endoplasmic reticulum residual signal peptide according to the present invention is not limited in type or amino acid sequence as long as it is a plant residual endoplasmic reticulum signal peptide known to those skilled in the art, but preferably includes or may consist of HDEL (His-Asp-Glu-Leu), HEEL (His-Glu-Glu-Leu), KDEL (Lys-Asp-Glu-Leu), KEEL (Lys-Glu-Glu-Leu), RDEL (Arg-Asp-Glu-Leu), or REEL (Arg-Glu-Glu-Leu).
[0074] In the present invention, the polynucleotide encoding the endoplasmic reticulum residual signal may include or be composed of a nucleotide sequence encoding HDEL (His-Asp-Glu-Leu), HEEL (His-Glu-Glu-Leu), KDEL (Lys-Asp-Glu-Leu), KEEL (Lys-Glu-Glu-Leu), RDEL (Arg-Asp-Glu-Leu), or REEL (Arg-Glu-Glu-Leu), but may include, without limitation, a nucleotide sequence that exhibits substantially the same or corresponding efficacy as said nucleotide sequence, or is composed thereof. Specifically, it may include a nucleotide sequence having sequence homology of 80% or more, preferably 90% or more, and more preferably 95% or more with said nucleotide sequence.
[0075] Information regarding signal peptides in the above vesicles and signal peptides remaining in the vesicles can be referenced in literature such as US20130295065, WO2009158716.
[0076] The gene construct according to the present invention may also further include a polynucleotide encoding a His-tag for the purpose of purifying recombinant DAL protein.
[0077] In the present invention, a polynucleotide encoding a His-tag for purifying a recombinant DAL protein may be located at the 3' end of a polynucleotide encoding the recombinant DAL protein.
[0078] In the present invention, the his-tag refers to a polyhistidine tag and comprises at least 6 histidine residues, preferably consisting of 6 to 20 histidine residues.
[0079] In the present invention, the gene construct may be in the form in which the following (i) to (v) are sequentially connected:
[0080] (i) Polynucleotide encoding an endoplasmic reticulum signal peptide,
[0081] (ii) a polynucleotide encoding the recombinant DAL protein,
[0082] (iii) Polynucleotide encoding the His-tag and
[0083] (iv) Polynucleotide encoding an ER retention signal peptide.
[0084] The gene construct of the present invention may further include a promoter, which is a transcription initiation factor to which RNA polymerase binds; any operator sequence for regulating transcription; a sequence encoding a suitable mRNA ribosome binding site; a sequence for regulating the termination of transcription and translation; a terminator; a cloning site; and the like.
[0085] The above promoters may include, for example, a pEMU promoter, a MAS promoter, a histone promoter, a Clp promoter, a cauliflower mosaic virus-derived 35S promoter, a cauliflower mosaic virus-derived 19S RNA promoter, a plant actin protein promoter, a ubiquitin protein promoter, a CMV (Cytomegalovirus) promoter, an SV4 (Simian virus 40) promoter, an RS (Respiratory syncytial virus) promoter, an EF-1α (Elongation factor-1 alpha) promoter, a pEMU promoter, a MAS promoter, a histone promoter, a Clp promoter, a MacT (CaMV 35S+MAS; in which the 3' terminal nucleotide of the Mac promoter is substituted with T) promoter, etc., and the above terminator may include, for example, nophalin synthase (NOS), Rice amylase RAmy1 A terminator, phaseolin terminator, terminator of the octopine gene of Agrobacterium toumafaciens, rrnB1 / B2 terminator of Escherichia coli, HSP18.2 terminator of Arabidopsis thaliana, RD29B terminator of Arabidopsis thaliana, etc. may be included, but the above-mentioned items are merely examples and are not limited thereto.
[0086] The term “cloning site” above refers collectively to a component inserted within a vector for the purpose of linking / separating each gene. Preferably, the cloning site may be the sequence indicated by “tctaga”, the sequence indicated by “ggatcc”, the sequence indicated by “cccggg”, the sequence indicated by “gagctc”, or the sequence indicated by “ctcgag” in the nucleotide sequence of SEQ ID NO. 13, but is not limited thereto.
[0087] A gene construct according to one embodiment of the present invention may include an expression cassette of FIG. 1. The "expression cassette" refers to a nucleic acid construct containing elements necessary to express a target product. Specifically, it refers to a nucleic acid construct comprising an expression regulatory region including at least a promoter and a nucleic acid for expressing a target product operably connected to the expression regulatory region.
[0088] The gene construct including the expression cassette of FIG. 1 above may include the nucleotide sequence of SEQ ID NO. 13 or be composed thereof.
[0089] A second aspect of the present invention relates to a recombinant vector comprising the various forms of gene constructs described above and a transformant transformed therefrom.
[0090] In this specification, “recombinant vector” refers to a vector capable of expressing a peptide or protein encoded by a heterogeneous nucleic acid inserted into the vector, preferably meaning a vector prepared to express a target antigen (in the present invention, vaccinia virus recombinant DAL protein). The “vector” refers to any medium for the introduction and / or transfer of bases into a host cell in vitro, in vitro, or in vivo, and may be a replica unit (replicon) capable of binding to another DNA fragment to bring about the replication of the bound fragment, and “replicon” refers to any genetic unit (e.g., plasmid, phage, cosmid, chromosome, virus, etc.) that functions as a self-unit of DNA replication in vivo, that is, capable of replication by self-regulation.
[0091] The vector used for the expression of the gene construct according to the present invention may be an expression vector known in the art.
[0092] A recombinant vector according to a specific embodiment of the present invention can be expressed in a plant or plant cell, and accordingly, the vector can use a binary vector that is typically used for the transformation of a plant or plant cell.
[0093] In the present invention, the "plant" may be used without limitation as long as it is a plant capable of mass-producing vaccinia virus recombinant DAL protein, but specifically, it may be selected from the group consisting of tobacco, Arabidopsis thaliana, corn, rice, soybean, canola, alfalfa, sunflower, alfalfa, sorghum, wheat, cotton, peanut, tomato, potato, lettuce, and chili pepper, and preferably, it may be tobacco. The tobacco in the present invention is a plant of the genus Nicotiana that is capable of overexpressing the protein and is not particularly limited in type, and the present invention may be carried out by selecting an appropriate variety to suit the purpose of the transformation method and the mass production of the protein. For example, varieties such as Nicotiana benthamiana L. or Nicotiana tabacum cv. Xanthi may be used.
[0094] When a recombinant vector according to a specific embodiment of the present invention is expressed in a plant, the aforementioned gene construct may include a nucleotide sequence that is codon-optimized for the plant, or a gene construct formed therefrom. For example, if the plant is Nicotiana benthamiana L. or Nicotiana tabacum cv. Xanthi, the gene construct may include the nucleotide sequence of SEQ ID NO. 13 that is codon-optimized for Nicotiana benthamiana L. or Nicotiana tabacum cv. Xanthi, or be formed therefrom.
[0095] As is well known in the art, in order to increase the expression level of a transformed gene in a host cell, the gene must be operably linked to a transcriptional and translational expression regulatory sequence. Preferably, the expression regulatory sequence and the gene are contained within a single recombinant vector that includes both a bacterial selection marker and a replication origin. It is preferable that the recombinant vector further include an expression marker useful in plant cells. A plant or plant cell transformed by the aforementioned recombinant vector constitutes another aspect of the present invention. As used herein, the term "transformation" means the introduction of DNA into a host so that the DNA becomes replicable as an extrachromosomal factor or through chromosomal integration. Meanwhile, "transfection" means the introduction of DNA into a host cell so that it becomes replicable within the host cell.
[0096] Of course, it must be understood that not all vectors function equally in expressing gene constructs within the system of the present invention. However, those skilled in the art can make appropriate selections from among various vectors and expression control sequences without excessive experimental burden and without departing from the scope of the present invention. The copy number of the vector, the ability to control the copy number, and the expression of other proteins encoded by said vector, such as antibiotic markers, must also be taken into consideration.
[0097] A preferred example of a recombinant vector of the present invention is a Ti-plasmid vector capable of transferring a portion of itself, the so-called T-region, into a plant cell when present in a suitable host, such as Agrobacterium tumefaciens. Other types of Ti-plasmid vectors (see EP 0 116 718 B1) are currently used to transfer hybrid DNA sequences into plant cells or protoplasts from which new plants can be produced by appropriately inserting the hybrid DNA into the plant genome. A particularly preferred form of a Ti-plasmid vector is a so-called binary vector as claimed in EP 0 120 516 B1 and U.S. Patent No. 4,940,838. Other suitable vectors that can be used to introduce the gene construct according to the present invention into a plant host may be selected from viral vectors, such as those derived from double-stranded plant viruses (e.g., CaMV) and single-stranded viruses, Gemini viruses, etc., e.g., incomplete plant viral vectors. The use of such vectors may be particularly advantageous when it is difficult to properly transform the plant host.
[0098] The expression vector will preferably include one or more selectable markers. The markers are nucleic acid sequences having characteristics that can typically be selected by chemical methods, and include all genes capable of distinguishing transformed cells from non-transformed cells. Examples include, but are not limited to, herbicide resistance genes such as glyphosate or phosphinothricin, and antibiotic resistance genes such as kanamycin, G418, bleomycin, hygromycin, and chloramphenicol.
[0099] In the plant expression vector of the present invention, the promoter can be appropriately selected and used from among the types of promoters described above.
[0100] In the present invention, since the selection of the transformant can be made by various tissues at various stages, a constitutive promoter may be preferred in the present invention. The "constitutive promoter" is a promoter that is active under most environmental conditions, developmental states, or cell differentiation. Therefore, the constitutive promoter does not limit the possibility of selection.
[0101] In the recombination vector of the present invention, the terminator can be appropriately selected and used from among the types of terminators described above.
[0102] In the present invention, "transgenic organism" refers to a living organism produced by injecting an external gene using molecular genetic methods, preferably a living organism transformed by the recombinant expression vector of the present invention, and there are no limitations on the living organism, such as microorganisms, eukaryotic cells, insects, animals, and plants, and preferably E. coli, Salmonella, Bacillus, yeast, animal cells, mice, rats, dogs, monkeys, pigs, horses, cattle, Acrobacterium tumerafascians, plants, etc., but is not limited thereto.
[0103] At this time, since the type of the "plant" mentioned above is the same as previously stated, its description is omitted.
[0104] The above-mentioned transformant may be produced by methods such as transformation, transfection, Agrobacterium-mediated transformation, particle gun bombardment, sonication, electroporation, and PEG (Polyethylene glycol)-mediated transformation, but there are no limitations as long as the method can inject the vector of the present invention.
[0105] A third aspect of the present invention relates to a vaccinia virus recombinant antigen protein and a method for producing the same.
[0106] In the present invention, the vaccinia virus recombinant antigen protein may be a vaccinia virus recombinant DAL protein comprising the amino acid sequence of SEQ ID NO. 3 or composed thereof. The vaccinia virus recombinant DAL protein may be prepared using a gene construct according to the first aspect of the present invention, or a recombinant vector or transformant according to the second aspect of the present invention.
[0107] Specifically, the method for producing a vaccinia virus recombinant antigen protein of the present invention may include the following steps (a) and (b):
[0108] (a) transforming a recombinant vector according to the second aspect of the present invention into a plant cell or plant; and
[0109] (b) A step of isolating and purifying vaccinia virus recombinant DAL protein from the above plant cell or plant.
[0110] In the present invention, step (a) may include transient expression or stable transformation of the gene construct according to the first aspect in a plant cell or plant transformed through a vector.
[0111] In addition to the gene construct according to the first aspect above being transiently expressed in a transgenic plant or plant cell, the gene construct can be stably transformed by being introduced into the genome of the transgenic plant or plant cell and existing as a chromosomal factor. It will be obvious to those skilled in the art to which the present invention pertains that inserting a gene targeting the vaccinia virus recombinant DAL protein into a plant genome chromosome will produce the same effect.
[0112] In the present invention, the introduction of a vector containing the gene construct or the chromosomal insertion of a gene construct encoding a vaccinia virus recombinant DAL protein can be performed by adding Agrobacterium containing a vector containing a gene construct encoding a vaccinia virus recombinant DAL protein to a population of plant cells and co-culturing them.
[0113] In one embodiment, the co-culture may be performed under dark conditions. The co-culture involves culturing a culture of Agrobacterium containing a vector containing a gene construct encoding the vaccinia virus recombinant DAL protein and a plant cell while stirring, and may further include a stationary culture step.
[0114] In this way, the gene construct encoding the vaccinia virus recombinant DAL protein can be transiently expressed or undergo stable transformation in plant cells via a vector.
[0115] The above static culture is a method of culturing in a container while it is stationary without stirring the culture medium, and in this invention, it may be used in combination with immersion without stirring.
[0116] The above static culture may be included in the form of a single or intermittent culture.
[0117] When a single static culture is included, for example, the method may be characterized by co-culturing plant cells and Agrobacterium cultures while stirring, and then performing a static culture followed by a stirring culture again. When intermittent static culture is included, the culture pattern of co-culturing plant cells and Agrobacterium cultures while stirring, performing a static culture followed by a stirring culture again, may be repeated several to tens of times.
[0118] In detail, the culture may be characterized by co-culturing the plant cell and a culture of Agrobacterium containing a vector containing a gene construct encoding the vaccinia virus recombinant DAL protein with stirring for 1 minute to 48 hours, then statically culturing for 1 minute to 96 hours, and then stirring again for 1 to 10 days. The OD600 of the Agrobacterium added for co-culturing may be 0.00001 to 2.0.
[0119] If the OD600 of Agrobacterium is too low, there is a problem with a low infection rate of transformation for transient expression, and if it is too high, there is a problem with a rapid decrease in the survival rate of host cells. Therefore, it is desirable to co-culture by adding Agrobacterium having an OD600 within the range defined above.
[0120] In this case, the Agrobacterium used for plant transformation can be the Agrobacterium commonly used, and for example, Agrobacterium tumefaciens or Agrobacterium rhizogenes can be used.
[0121] Transformation of a plant refers to any method of transferring DNA into a plant. Such transformation methods do not necessarily require a period of regeneration and / or tissue culture. Transformation of plant species is now common for plant species including both dicotyledonous and monocotyledonous plants. In principle, any transformation method may be used to introduce hybrid DNA according to the present invention into a suitable progenitor cell. The method may be suitably selected from the calcium / polyethylene glycol method for protoplasts, electroporation of protoplasts, microinjection into plant elements, particle impaction of various plant elements (DNA or RNA-coated), infection by (incomplete) viruses in Agrobacterium tumopaciens-mediated gene transfer by infiltration of the plant or transformation of mature pollen or microspores. A preferred method according to the present invention comprises Agrobacterium-mediated DNA transfer.
[0122] In the present invention, the vaccinia virus recombinant DAL protein expressed in the plant cell or plant may be in a water-soluble form. More specifically, the vaccinia virus recombinant DAL protein expressed in the plant cell or plant may be 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% dissolved in a water-soluble fraction.
[0123] Step (b) above may involve recovering the vaccinia virus recombinant DAL protein by purifying the total soluble protein extract obtained by crushing the plant cell or tissue separated from the plant using affinity chromatography.
[0124] A fourth aspect of the present invention relates to an orthophoxvirus vaccine composition comprising the aforementioned vaccinia virus recombinant DAL protein.
[0125] As used herein, the term "vaccine" refers to a biological preparation containing an antigen that imparts immunity to a living organism, and means an immunogen or antigenic substance that induces immunity in a living organism by injecting or orally administering it to humans or animals for the prevention of infectious diseases.
[0126] The vaccine composition of the present invention may further contain one or more adjuvants selected from the group consisting of stabilizers, emulsifiers, aluminum hydroxide, aluminum phosphate, pH adjusters, surfactants, liposomes, iscom adjuvants, synthetic glycopeptides, extenders, carboxypolymethylene, subviral particle adjuvants, cholera toxins, N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine, monophosphoryl lipid A, dimethyldioctadecyl-ammonium bromide, and mixtures thereof.
[0127] The vaccine composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, nasal formulations such as drips or sprays, and sterile injectable solutions, each according to conventional methods. When formulating, the composition may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and these solid dosage forms may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the lecithin-like emulsifier mentioned above. In addition, lubricants such as magnesium styrate and talc may also be used in addition to simple excipients. Liquid formulations for oral administration may include suspensions, liquid formulations, emulsions, syrups, etc., and may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, water-insoluble formulations, suspensions, emulsions, and lyophilized formulations. Water-insoluble formulations and suspensions may include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleates. Penetrating agents suitable for formulations for intranasal administration are generally known to those skilled in the art. Such suitable formulations are preferably formulated to be sterile, isotonic, and buffered for stability and compliance. Preparations for intranasal administration are also formulated to stimulate mucus secretion in various ways to maintain normal ciliary function, and literature (Remington's Pharmaceutical Science, 18th Ed., Mack Publishing Co.As described in , Easton, PA (1990), it may preferably be an isotonic buffered formulation maintaining a pH of 5.5 to 6.5, and may additionally include an antimicrobial preservative and a suitable drug stabilizer.
[0128] The vaccine composition of the present invention may additionally include a carrier or an adjuvant. The adjuvant may be aluminum hydroxide, GEL O1, GEL O2, IMS 1313(VG), IMS 1313(VG N), ISA 15A(VG), ISA 28R(VG), ISA 35(VG), ISA 201(VG), ISA 206(VG), ISA 660(VG), a water-in-oil emulsion, an incomplete Freund's adjuvant, alum, aluminum hydroxide, a Toll-like receptor agonist, an immunostimulatory oligonucleotide, or a biological adjuvant, and preferably may be IMS 1313(VG). The above-mentioned carrier includes any and all solvents, dispersion media, coating agents, adjuvants, stabilizers, diluents, preservatives, antimicrobial and antifungal agents, isotonic agents, adsorption retardants, etc. Carriers, excipients, and diluents that may be included in a vaccine composition may be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, glycerin, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, etc.
[0129] In the present invention, the vaccinia virus recombinant DAL protein can be prepared using a recombinant vector according to the second aspect described above.
[0130] In a specific embodiment of the present invention, changes in body weight and survival rates of mice were measured following vaccinia virus challenge after administration of the aforementioned vaccinia virus recombinant DAL protein vaccine, confirming that the vaccine containing the vaccinia virus recombinant DAL protein has a preventive effect against Orthofoxvirus species (Fig. 4). In addition, the reduction rate of vaccinia virus plaques compared to a control group (cultured only with vaccinia virus) was measured according to the dilution ratio of mouse serum after administration of the aforementioned vaccinia virus recombinant DAL protein vaccine, confirming that the vaccine containing the vaccinia virus recombinant DAL protein forms neutralizing antibodies (Fig. 5). As such, the vaccinia virus recombinant DAL protein according to the present invention generates neutralizing antibodies against Orthofoxvirus species and exhibits protective efficacy against them, so it can be used as a vaccine to prevent infection with Orthofoxvirus species.
[0131] In the present invention, the orthopoxvirus may be a smallpox virus, a vaccinia virus, a cowpox virus, or a monkeypox virus.
[0132] The vaccine composition of the present invention may be administered orally or parenterally (e.g., intramuscularly, intravenously, subcutaneously, intraperitoneally, or locally) depending on the intended method, and preferably may be administered orally or intramuscularly, but is not limited thereto.
[0133] The above vaccine composition may be administered to humans or animals. In addition, the dosage of the above composition varies depending on the subject's weight, age, gender, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease.
[0134] The recombinant protein of the present invention may be administered in an amount of 0.1 μg to 1000 μg based on a volume of 1 ml of vaccine composition, preferably 1 μg to 100 μg, and most preferably 10 μg.
[0135] The present invention will be explained in more detail below through examples. However, the present invention is
[0136] As various modifications may be made and various forms may be taken, the specific embodiments and descriptions provided below are intended only to aid in understanding the invention and are not intended to limit the invention to the specific disclosed forms. The scope of the invention should be understood to include all modifications, equivalents, and substitutions that fall within the spirit and technical scope of the invention.
[0137] The amino acid sequence and base sequence used in the present invention are shown in Table 1 below.
[0138]
[0139]
[0140] The underlined part is the sequence corresponding to the vaccinia virus recombinant DAL protein.
[0142] Example 1: Preparation of a recombinant vector expressing vaccinia virus DAL antigen
[0143] A plant expression vector was constructed to enable the expression of the vaccinia virus DAL in plants.
[0144] To this end, as shown in Figure 1, a gene construct encoding DAL was synthesized by codon optimization for the tobacco plant Nicotiana benthamiana L. or Nicotiana tabacum.
[0145] DAL utilized two regions from amino acid sequence positions 90-181 (A33_1) and 64-181 (A33_2) of the A33 protein and a region from amino acid sequence position 3-181 of the L1 protein, and was constructed with the structure “A33_1 - L1_1 - A33_2 - L1_1”. To accumulate the DAL protein in the endoplasmic reticulum, an NB signal peptide was fused to the protein N-terminus, and a peptide (HHHHHHDEL) consisting of a 6 x His tag for protein purification and an HDEL tetrapeptide, an endoplasmic reticulum residual signal peptide, was fused to the C-terminus.
[0146] The gene construct designed as described above was cloned into a pTEX vector to construct a plant expression vector.
[0148] Example 2: Confirmation of DAL antigen expression
[0149] 2-1. Transient expression of DAL expression vectors
[0150] The plant expression vector prepared in Example 1 above was transformed into the Agrobacterium GV3101 strain using electroporation. The transformed Agrobacterium was cultured with shaking in 5 mL of YEP liquid medium (YEP medium, kanamycin 50 mg / L, rifampicin 25 mg / L) at 28°C for 16 hours, and then 1 mL of the primary culture was inoculated into 50 mL of new YEP medium and cultured with shaking at 28°C for 16 hours. The cultured Agrobacteria were collected by centrifugation (7,000 rpm, 4°C, 5 min) and suspended in infiltration buffer [10 mM MES (pH 5.7), 10 mM MgCl2, 100 μM acetosyringone] to achieve an absorbance (OD) value of 0.5 at a wavelength of 600 nm. The Agrobacteria suspension was then [supposedly omitted] using a syringe from which the needle had been removed, Nicotiana ventamiana ( Nicotiana benthamiana Agro-infiltration was performed by injecting into the underside of the leaves.
[0151] 2-2. Confirmation of DAL Protein Expression
[0152] Proteins were extracted from the plant leaves prepared in Example 2-1 above and centrifuged. Subsequently, the proteins in the supernatant (S), the proteins in the pellet (Pellet; P) fraction, and the fraction containing both the supernatant and pellet (Total; T) were separated, and the expression of recombinant DAL protein was confirmed by Western blotting. More specifically, 10 μL of each fraction was mixed with SDS sample buffer and heated. The prepared samples were then subjected to electrophoresis on a 10% SDS-PAGE gel to identify protein bands separated by size. After transferring the samples to a PVDF membrane, a blocking step was performed using 5% skim milk. Subsequently, an antibody reacting with polyhistidine and a secondary antibody conjugated with HRP were sequentially conjugated, and the expression of recombinant DAL protein was confirmed by treating with an ECL solution according to the method provided by the manufacturer.
[0153] As a result, as shown in Figure 2, it was confirmed that the recombinant DAL antigen protein was expressed with high efficiency, and most of the expressed recombinant DAL protein was found in the water-soluble fraction.
[0155] Example 3: Purification of Recombinant DAL Protein
[0156] 2 L of protein extraction solution (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 30 mM imidazole, 0.5% Triton X-100, 100 mM Sodium sulfite, 1.5% PVPP) was added to 1 kg of Nicotiana bentamia leaves expressing recombinant DAL protein, and the tissue was crushed with a blender. The plant debris was removed by centrifugation at 12,000 xg at 4°C for 40 minutes, and the protein extract was recovered. Affinity chromatography was performed using Ni-NTA agarose resin to isolate and purify the recombinant DAL protein from the protein extract.
[0157] Proteins were adsorbed from approximately 100 mL of resin and protein extract, equilibrated with wash solution 2 (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 30 mM Imidazole), using a magnetic stirrer for 1 hour. The protein-adsorbed resin was packed into a column and mounted on an FPLC. Then, 1.5 L each of wash solution 1 (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 30 mM Imidazole, 0.5% Triton X-100) and wash solution 2 were passed through sequentially to wash the plant extracts adsorbed on the resin, and 500 mL of elution solution (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 300 mM Imidazole) was passed through to elute the recombinant DAL protein from the resin. The elution solution containing recombinant DAL protein was buffer-replaced and concentrated with the final solution (50 mM Tris-HCl (pH 8.0), 300 mM NaCl) using a 30 kDa filter. The isolated and purified recombinant DAL protein was confirmed by Coomassie staining after electrophoresis (SDS-PAGE).
[0158] As a result, it was confirmed that the recombinant DAL protein was purified, as shown in Figure 3.
[0160] Example 4: Confirmation of protective effect against vaccinia virus by DAL antigen vaccine
[0161] To confirm the infection-preventive effect of administering the vaccinia virus DAL antigen protein isolated and purified in Example 3 and the stability of the vaccine, a protective ability test was performed on a total of 40 6-week-old female BALB / c mice, divided into 4 groups of 10 mice each. Specifically, the vaccine contained 1, 5, and 10 μg of Alum-treated control and DAL, respectively, and 100 μg of vaccine was administered to each mouse per dose. A vaccine was prepared by mixing the recombinant protein antigen cocktail with an Alum adjuvant, and three intramuscular injections were administered at 2-week intervals. One week after the third injection, 10 mice in each group were challenged with the vaccinia virus.
[0162] The results of changes in body weight and survival rates of mice following challenge inoculation are shown in Figure 4. All mice in the Alum-treated control group died on the 8th day after being challenged with the vaccinia virus, but all 10 mice survived when DAL vaccines were administered at 1, 5, and 10 µg, respectively.
[0163] As a result, as shown in Figure 4, it was confirmed that the DAL antigen vaccine has a preventive effect against Ortholoxvirus genus viruses.
[0165] Example 5: Evaluation of neutralizing antibodies following DAL antigen vaccination
[0166] In order to perform the protective ability test in Example 4, blood was collected from mice 7 days after administering three intramuscular injections of DAL 1, 5, and 10 µg antigen vaccines at 2-week intervals, and serum was isolated. Serum from 10 mice of the same group was pooled, and neutralizing antibodies were analyzed using the PRNT (Plaque reduction neutralization test). The control group serum and the experimental group serum were each diluted at the same dilution ratio. Vaccinia virus with confirmed titer (PFU / ml) was diluted to prepare a virus control with approximately 50 plaques / well, then mixed with the diluted serum in a 1:1 ratio and reacted at 37°C for 1 hour. The serum and virus reaction solution was then inoculated into Vero cells, adsorbed for 5 hours, and then 1% Sea plaque agar medium was added. The cells were incubated for 3 days in a 37°C, 5% CO2 incubator, and then stained with 1% crystal violet to count the plaques. The plaque reduction ratio was measured compared to the control cultured only with the virus.
[0167] As a result, as shown in Figure 5, neutralizing antibodies against vaccinia virus were confirmed in the serum of mice vaccinated with the DAL antigen vaccine.
[0169] Although specific embodiments regarding the vaccinia virus recombinant DAL protein and the orthofox virus vaccine composition containing the same according to one embodiment of the present invention have been described so far, it is obvious that various modifications are possible within the scope of the present invention.
[0170] Therefore, the scope of the present invention should not be limited to the described embodiments, but should be defined by the claims set forth below as well as equivalents thereof.
[0171] That is, the aforementioned embodiments should be understood as exemplary in all respects and not limiting, and the scope of the invention is defined by the claims set forth below rather than by the detailed description, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts thereof should be interpreted as being included within the scope of the invention.
Claims
Claim 1 A gene construct comprising a polynucleotide encoding a vaccinia virus recombinant DAL protein, comprising the amino acid sequence from position 90 to 181 in the amino acid sequence of SEQ ID NO. 1, the amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO. 2, the amino acid sequence from position 64 to 181 in the amino acid sequence of SEQ ID NO. 1, and the amino acid sequence from 3 to 181 in the amino acid sequence of SEQ ID NO.
2. Claim 2 In claim 1, the recombinant DAL protein is a gene construct comprising the amino acid sequence of SEQ ID NO.
3. Claim 3 A gene construct according to claim 1, further comprising a polynucleotide encoding an endoplasmic reticulum signal peptide and / or a polynucleotide encoding an endoplasmic reticulum retention signal peptide. Claim 4 A gene construct according to paragraph 3, further comprising a polynucleotide encoding a His-tag. Claim 5 In paragraph 3, the polynucleotide encoding the endoplasmic reticulum signal peptide comprises the nucleotide sequence of SEQ ID NO. 5 encoding a new chaperone binding protein (NB), forming a gene construct. Claim 6 In paragraph 3, the above-mentioned endoplasmic reticulum residual signal peptide comprises a gene construct having an amino acid sequence of HDEL (His-Asp-Glu-Leu), HEEL (His-Glu-Glu-Leu), KDEL (Lys-Asp-Glu-Leu), KEEL (Lys-Glu-Glu-Leu), RDEL (Arg-Asp-Glu-Leu), or REEL (Arg-Glu-Glu-Leu). Claim 7 In paragraph 3, a gene construct in which the following (i) to (iv) are sequentially linked: (i) a polynucleotide encoding an endoplasmic reticulum signal peptide, (ii) a polynucleotide encoding the recombinant DAL protein, (iii) a polynucleotide encoding a His-tag, and (iv) a polynucleotide encoding an endoplasmic reticulum retention signal peptide. Claim 8 In claim 7, the gene construct comprises the nucleotide sequence of SEQ ID NO.
13. Claim 9 A recombinant vector comprising a gene construct of any one of claims 1 to 8. Claim 10 A transformant transformed by a recombinant vector of claim 9, wherein the transformant is a human body. Claim 11 In Clause 10, the above-mentioned transformant is a transformant that is a plant body. Claim 12 A method for producing a vaccinia virus recombinant antigen protein comprising the following (a) and (b): (a) transforming a plant body with the recombinant vector of claim 9; and (b) isolating and purifying a vaccinia virus recombinant DAL protein from the plant body. Claim 13 A method for producing a vaccinia virus recombinant antigen protein, wherein the vaccinia virus recombinant DAL protein is expressed in a water-soluble form in the plant body, in accordance with claim 12. Claim 14 Vaccinia virus recombinant antigen protein containing the amino acid sequence of SEQ ID NO.
3. Claim 15 In claim 14, the above protein is a vaccinia virus recombinant antigen protein produced from a plant or plant cell transformed with a recombinant vector containing the gene construct of claim 1. Claim 16 An orthofoxvirus vaccine composition comprising the vaccinia virus recombinant antigen protein of claim 14. Claim 17 A composition according to claim 16, wherein the orthopoxvirus is a smallpox virus, a vaccinia virus, or a monkeypox virus.
